• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Acta Biomed . COVID-19 serological evaluation in a cohort of Vaccinated and Seropositive healthcare workers

tetano

Editor, Senior Moderator
Acta Biomed


. 2021 Oct 19;92(S6):e2021415.
doi: 10.23750/abm.v92iS6.12261.
COVID-19 serological evaluation in a cohort of Vaccinated and Seropositive healthcare workers


Smeralda D'Amato[SUP] 1 [/SUP], Raffaele Squeri[SUP] 2 [/SUP], Vincenza La Fauci[SUP] 3 [/SUP], Giuseppe Pantò[SUP] 4 [/SUP], Ennrica Maria Esposito[SUP] 5 [/SUP], Federica Denaro[SUP] 6 [/SUP], Giovanna Visalli[SUP] 7 [/SUP], Ioselita Giunta[SUP] 8 [/SUP], Roberto Venuto[SUP] 9 [/SUP], Antonino Privitera[SUP] 10 [/SUP], Lorenzo D'Urso[SUP] 11 [/SUP], Rosaria Cortese[SUP] 12 [/SUP], Francesco Mazzitelli[SUP] 13 [/SUP], Concetta Ceccio[SUP] 14 [/SUP], Franco Fedele[SUP] 15 [/SUP], Daniele Maisano[SUP] 16 [/SUP], Giuseppe Trimarchi[SUP] 17 [/SUP], Cristina Genovese[SUP] 18 [/SUP]



Affiliations

Abstract

Introduction: Severe Acquired Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) infection represents an unprecedented public health problem and, at present, vaccination is the only weapon available to combat the infection. The simplest and most immediate method to quantify the response of the subject's immune system to vaccination and / or infection is the serological assessment of the antibody titer. The objective of our study was 1) to evaluate the presence of antibody responses in a sample of healthcare workers subjected to a complete vaccination course as per ministerial provisions (double dose for negatives and single dose for ex-SARS-CoV subjects -2 positive) with Comirnaty vaccine (Pfizer / BioNTech) 2) evaluate the presence of statistically significant associations for sex, age and previous positive swab.
Materials and methods: the antibody levels of both nucleocapsid antibodies and anti-Sars-CoV2 Spike antibodies of the study subjects were examined with the electrochemiluminescent immunoassay (ECLIA) method developed by Roche®. The cut-off value, as suggested by the manufacturer, for anti-nucleocapsid antibodies was 1 COI, while the Ig Spike value was 0.8 I / mL. The study sample was stratified by age (≤45 years, 46-55, ≥56 years old), previous positive molecular swab, gender and IgG S1 / S2 values ​​at the completed vaccination course (≤200, ≥200 AU / mL ). Statistical analyzes were carried out with the R software.
Results: almost all of the sample (89.45%) showed IgG Spike values> 200 AU / mL with statistically significant associations in relation to sex (greater in females, p≤0.05), to previous swab positivity in the presence of a vaccine dose (n = 44; p <0.001) and at age (with greater antibody response in subjects under 45; p <0.001).
Discussion and conclusions: The current study confirms what is reported in the literature. In the light of the results obtained, it could be interesting to promote studies that evaluate the antibody titers trend over time a) in women of childbearing age and postmenopausal age b) in particular categories of subjects with chronic degenerative diseases to assess the actual need for doses booster, it being understood that the immune system response is guaranteed by both cellular and humoral immunity and that the antibody titer does not faithfully reflect the protection obtained.
 
Back
Top Bottom